Natural Product (NP) Details
General Information of the NP (ID: NP1047) | |||||
---|---|---|---|---|---|
Name |
Zerumbone
|
||||
Synonyms |
Zerumbone; 471-05-6; (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; (E,E,E)-2,6,9,9-Tetramethyl-2,6,10-cycloundecatrien-1-one; CHEMBL245412; 2E,6E,9E-humulatrien-8-one; CHEBI:63892; C15H22O; Zerumbone (6CI,7CI); 2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; SCHEMBL12831266; Zerumbone, >=98% (HPLC); HY-N7015; BDBM50241296; MFCD03700769; NSC698299; s5928; ZINC28878195; CCG-208558; NSC-698299; CS-0003365; C20262; Q27132897
Click to Show/Hide
|
||||
Species Origin | Zingiber zerumbet ... | Click to Show/Hide | |||
Zingiber zerumbet | |||||
Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H22O
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C
|
||||
InChI |
1S/C15H22O/c1-12-6-5-7-13(2)14(16)9-11-15(3,4)10-8-12/h7-9,11H,5-6,10H2,1-4H3/b11-9+,12-8+,13-7+
|
||||
InChIKey |
GIHNTRQPEMKFKO-SKTNYSRSSA-N
|
||||
CAS Number |
CAS 471-05-6
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Nimesulide | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
In-vivo Model | Colitis was induced in female ICR mice at 7 weeks of age. | |||||
Experimental
Result(s) |
ZER is a novel food factor for mitigating experimental UC and that use of a combination of agents, with different modes of actions, may be an effective anti-inflammatory strategy. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
In-vivo Model | Inbred BALB/c mice with CIN were injected peritoneally with isotonic sodium chloride solution (positive control), CIS, ZER, and a combination of both compounds. | |||||
Experimental
Result(s) |
The combination of ZER and CIS has modulated the serum level of interleukin 6 when compared with that in mice treated with isotonic sodium chloride solution. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Baculoviral IAP repeat-containing 1 (AKT1S1) | Molecule Info | [4] | |
Caspase-3 (CASP3) | Molecule Info | [4] | ||
Forkhead box protein O1A (FOXO1) | Molecule Info | [4] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | p53 signaling pathway | |||
3 | Apoptosis | |||
4 | Natural killer cell mediated cytotoxicity | |||
5 | TNF signaling pathway | |||
6 | Serotonergic synapse | |||
7 | Non-alcoholic fatty liver disease (NAFLD) | |||
8 | Alzheimer's disease | |||
9 | Parkinson's disease | |||
10 | Amyotrophic lateral sclerosis (ALS) | |||
11 | Huntington's disease | |||
12 | Epithelial cell signaling in Helicobacter pylori infection | |||
13 | Pertussis | |||
14 | Legionellosis | |||
15 | Toxoplasmosis | |||
16 | Amoebiasis | |||
17 | Tuberculosis | |||
18 | Hepatitis B | |||
19 | Herpes simplex infection | |||
20 | Pathways in cancer | |||
21 | Viral carcinogenesis | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Colorectal cancer | |||
25 | Viral myocarditis | |||
26 | FoxO signaling pathway | |||
27 | AMPK signaling pathway | |||
28 | Insulin signaling pathway | |||
29 | Thyroid hormone signaling pathway | |||
30 | Glucagon signaling pathway | |||
31 | Transcriptional misregulation in cancer | |||
32 | Prostate cancer | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | IL2 Signaling Pathway | |||
3 | IL4 Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | FAS signaling pathway | |||
3 | Huntington disease | |||
4 | CCKR signaling map ST | |||
5 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
6 | PI3 kinase pathway | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
3 | FAS (CD95) signaling pathway | |||
4 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
5 | Posttranslational regulation of adherens junction stability and dissassembly | |||
6 | p75(NTR)-mediated signaling | |||
7 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
8 | Caspase Cascade in Apoptosis | |||
9 | Syndecan-2-mediated signaling events | |||
10 | Regulation of nuclear SMAD2/3 signaling | |||
11 | Signaling events mediated by HDAC Class III | |||
12 | Angiopoietin receptor Tie2-mediated signaling | |||
13 | CXCR4-mediated signaling events | |||
14 | FoxO family signaling | |||
15 | Regulation of Androgen receptor activity | |||
16 | IL6-mediated signaling events | |||
17 | Class I PI3K signaling events mediated by Akt | |||
Reactome | SMAC binds to IAPs | Click to Show/Hide | ||
2 | SMAC-mediated dissociation of IAP:caspase complexes | |||
3 | Apoptotic cleavage of cellular proteins | |||
4 | Degradation of the extracellular matrix | |||
5 | NADE modulates death signalling | |||
6 | Activation of DNA fragmentation factor | |||
7 | Caspase-mediated cleavage of cytoskeletal proteins | |||
8 | AKT phosphorylates targets in the nucleus | |||
9 | Regulation of gene expression in beta cells | |||
10 | AKT-mediated inactivation of FOXO1A | |||
11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
12 | MAPK6/MAPK4 signaling | |||
WikiPathways | DNA Damage Response | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | Apoptosis Modulation by HSP70 | |||
4 | MAPK Signaling Pathway | |||
5 | Copper homeostasis | |||
6 | FAS pathway and Stress induction of HSP regulation | |||
7 | Signaling by Hippo | |||
8 | Apoptosis | |||
9 | Amyotrophic lateral sclerosis (ALS) | |||
10 | Spinal Cord Injury | |||
11 | BDNF signaling pathway | |||
12 | Integrated Pancreatic Cancer Pathway | |||
13 | Oncostatin M Signaling Pathway | |||
14 | Parkinsons Disease Pathway | |||
15 | Corticotropin-releasing hormone | |||
16 | Allograft Rejection | |||
17 | AGE/RAGE pathway | |||
18 | TNF alpha Signaling Pathway | |||
19 | Prostate Cancer | |||
20 | Alzheimers Disease | |||
21 | TWEAK Signaling Pathway | |||
22 | Integrated Breast Cancer Pathway | |||
23 | Signalling by NGF | |||
24 | Integrated Cancer pathway | |||
25 | Regulation of Apoptosis | |||
26 | Intrinsic Pathway for Apoptosis | |||
27 | Apoptotic execution phase | |||
28 | Apoptosis Modulation and Signaling | |||
29 | miRNA Regulation of DNA Damage Response | |||
30 | ErbB Signaling Pathway | |||
31 | Insulin Signaling | |||
32 | EGF/EGFR Signaling Pathway | |||
33 | Pregnane X Receptor pathway | |||
34 | Endoderm Differentiation | |||
35 | Adipogenesis | |||
36 | B Cell Receptor Signaling Pathway | |||
37 | Signaling Pathways in Glioblastoma | |||
38 | FSH signaling pathway | |||
39 | Leptin signaling pathway | |||
40 | Regulation of beta-cell development | |||
41 | Androgen receptor signaling pathway |

